Renaissance Technologies - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,037
+228.5%
105,680
+210.1%
0.01%
+250.0%
Q2 2023$1,229
-66.2%
34,080
-64.2%
0.00%
-60.0%
Q1 2023$3,633
-54.9%
95,141
-32.8%
0.01%
-54.5%
Q4 2022$8,059
-99.9%
141,641
-60.5%
0.01%
-45.0%
Q3 2022$14,167,000
-33.6%
358,300
-26.2%
0.02%
-20.0%
Q2 2022$21,349,000
+157.7%
485,200
+133.6%
0.02%
+150.0%
Q1 2022$8,283,000
+63.5%
207,700
+64.8%
0.01%
+66.7%
Q4 2021$5,066,000
-18.7%
126,000
-17.8%
0.01%
-25.0%
Q3 2021$6,232,000
-77.8%
153,200
-77.3%
0.01%
-77.1%
Q1 2021$28,087,000
+24.5%
673,700
+27.6%
0.04%
+45.8%
Q4 2020$22,556,000
+62.6%
528,129
+0.1%
0.02%
+71.4%
Q3 2020$13,868,000
-48.7%
527,700
-47.7%
0.01%
-39.1%
Q2 2020$27,030,000
+364.6%
1,008,200
+211.8%
0.02%
+283.3%
Q1 2020$5,818,000
-73.1%
323,400
-73.5%
0.01%
-64.7%
Q4 2019$21,606,000
+174.2%
1,218,600
+165.7%
0.02%
+142.9%
Q2 2019$7,879,000
-34.7%
458,600
-38.8%
0.01%
-36.4%
Q1 2019$12,065,000
+170.8%
749,400
+146.0%
0.01%
+120.0%
Q4 2018$4,456,000
-58.5%
304,600
-48.4%
0.01%
-54.5%
Q3 2018$10,731,000
-66.8%
590,600
-66.7%
0.01%
-38.9%
Q2 2018$32,321,000
+84.7%
1,771,800
+98.3%
0.02%
-5.3%
Q1 2018$17,502,000
+17.3%
893,400
+21.3%
0.02%
+18.8%
Q4 2017$14,924,000
+10192.4%
736,600
+4910.9%
0.02%
Q4 2016$145,000
-88.0%
14,700
-85.3%
0.00%
-100.0%
Q3 2016$1,208,000
-66.0%
100,000
-73.3%
0.00%
-71.4%
Q1 2016$3,551,000
+2176.3%
375,000
+3132.8%
0.01%
Q3 2015$156,000
-95.6%
11,600
-92.6%
0.00%
-100.0%
Q2 2015$3,559,000
-34.6%
157,600
-58.6%
0.01%
-33.3%
Q1 2015$5,438,000
+625.1%
380,800
+390.1%
0.01%
+500.0%
Q4 2014$750,000
-73.7%
77,700
-73.1%
0.00%
-71.4%
Q2 2014$2,856,000
+66.0%
289,062
+113.5%
0.01%
+75.0%
Q1 2014$1,720,000
-61.8%
135,400
-54.9%
0.00%
-63.6%
Q4 2013$4,497,000300,0000.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders